Thibault Letellier

Dr. Thibault Letellier

Centre Hospitalier Universitaire de Nantes, Nantes, Pays de la Loire, France
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 November 2020 in Clinical Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
PDF file
TLThibault Letellier
Thibault Letellier
FLFlorent Leborgne
Florent Leborgne
CKClarisse Kerleau
Clarisse Kerleau
AGAurélie Gaultier
Aurélie Gaultier
JDJacques Dantal
Jacques Dantal
OCon behalf of Divat Consortium
on behalf of Divat Consortium
Background and objectives: Keratinocyte cancers, which primarily comprise squamous cell carcinomas and basal cell carcinomas, represent a major concern and potential risk for kidney transplant recipients. Hydrochlorothiazide, a diuretic widely used to treat hypertension, has been implicated in skin photosensitivity reaction. Recent studies conducted in the general population have found that hydrochlorothiazide use is associated with a higher risk of keratinocyte cancer, especially squamous cell carcinomas. High-risk groups, however, including transplant recipients were excluded from these. Our aim was to investigate whether hydrochlorothiazide use was associated with keratinocyte cancer in kidney transplant recipients on immunosuppressive therapy. Design, setting, participants, & measurements: In a single-center cohort of kidney (n=2155), combined kidney-pancreas (n=282), and pancreas (n=59) transplant recipients from the Données Informatisées VAlidées Transplantation (DIVAT) database transplanted between 2000 and 2017 in Nantes, France, we evaluated the association between hydrochlorothiazide exposure and keratinocyte cancers. Multivariable cause-specific, time-varying Cox models were used to estimate the relationship between hydrochlorothiazide exposure and the hazard of squamous cell carcinoma and basal cell carcinoma, with hydrochlorothiazide designated as the time-dependent variable. Results: Among the participants, 279 of 2496 (11%) were exposed to hydrochlorothiazide after the transplantation. Cumulative incidence rates of keratinocyte cancer by 10 and 15 years were 7% and 9% for squamous cell carcinomas, respectively, and 8% and 11% for basal cell carcinomas, respectively. We found a relationship between exposure to hydrochlorothiazide and the risk of squamous cell carcinomas (hazard ratio, 2.04; 95% confidence interval, 1.27 to 3.28). In contrast, we found no association between hydrochlorothiazide exposure and basal cell carcinomas (hazard ratio, 0.63; 95% confidence interval, 0.35 to 1.15). Conclusions: In a single-center cohort of kidney, combined kidney-pancreas, and pancreas transplant recipients, exposure to hydrochlorothiazide was associated with a two-fold higher risk of squamous cell carcinoma and no higher risk of basal cell carcinoma.

Verified
Journal Article
Open access
PDF file
TLThibault Letellier
Thibault Letellier
DKDelphine Kervella
Delphine Kervella
ASAbderrahmane Sadek
Abderrahmane Sadek
CMChristophe Masset
Christophe Masset
CGClaire Garandeau
Claire Garandeau
OCon behalf of the Divat Consortium
on behalf of the Divat Consortium
Introduction: In kidney transplant recipients, belatacept is usually pursued indefinitely after it has been started. In the setting of the belatacept shortage and after having evaluated the benefit–risk ratio, we established a strategy consisting of time-limited belatacept therapy/transient calcineurin inhibitor withdrawal, whose results are analyzed in that study. Methods: We considered all the kidney transplant recipients that had been switched from conventional immunosuppressive therapy to belatacept and then for whom belatacept has been withdrawn intentionally. Furthermore, in the first 8 patients, we assessed changes in peripheral blood mononuclear cells (PBMC) transcriptome using RNAseq before and 3 months after belatacept withdrawal. Results: Over the study period, 28 out of 94 patients had belatacept intentionally withdrawn including 25 (89%) switched to low-dose CNI. One rejection due to poor compliance occurred. The eGFR after 12 months remained stable from 48 ± 19 mL.1.73 m−2 to 46 ± 17 mL.1.73 m−2 (p = 0.68). However, patients that resumed belatacept/withdrew CNIs (n = 10) had a trend towards a better eGFR comparing with the others (n = 15): 54 ± 20 mL.1.73 m−2 vs. eGFR 43 ± 16 mL.1.73 m−2, respectively (p = 0.15). The only factor associated with belatacept resumption was when the withdrawal took place during the COVID-19 outbreak. Transcriptome analysis of PBMCs, did not support rebound in alloimmune response. Conclusions: These findings underpin the use of belatacept as part of a time-limited therapy, in selected kidney transplant recipients, possibly as an approach to allow efficient vaccination against SARS-CoV-2.

7 April 2022 in Preprints.org
Verified
Preprint
Open access
PDF file
TLThibault Letellier
Thibault Letellier
DKDelphine Kervella
Delphine Kervella
ASAbderrahmane Sadek
Abderrahmane Sadek
CMChristophe Masset
Christophe Masset
CGClaire Garandeau
Claire Garandeau
SVSimon Ville
Simon Ville
In kidney transplant recipients, belatacept is usually pursued indefinitely after it has been started. In the setting of the belatacept shortage and after having evaluated the benefit-risk ratio, we established a strategy consisting of time-limited belatacept therapy / transient calcineurin inhibitor withdrawal, whose results are analyzed in that study. We considered all the kidney transplant recipients that had been switched from conventional immunosuppressive therapy to belatacept and then for whom belatacept has been withdrawn intentionally. Furthermore, in the first 8 patients, we assessed changes in peripheral blood mononuclear cells (PBMC) transcriptome using RNAseq before and 3 months after belatacept withdrawal. Over the study period, 28 out of 94 patients had belatacept intentionally withdrawn including 25 (89%) switched to low-dose CNI. One rejection due to poor compliance occurred. The eGFR after 12 months remained stable from 48 ± 19 ml.1.73m-2 to 46 ±17 ml.1.73m-2 (p = 0.68). However, patients that resumed belatacept / withdrew CNIs (n=10) had a trend towards a better eGFR comparing with the others (n =15): 54 ± 20 ml.1.73m-2 vs eGFR 43 ± 16 ml.1.73m-2 respectively (p = 0.15). The only factor associated with belatacept resumption was when the withdrawal took place during the COVID-19 outbreak. Transcriptome analysis of PBMCs, did not support rebound in alloimmune response. These findings underpin the use of belatacept as part of a time-limited therapy, in selected kidney transplant recipients, possibly as an approach to allow efficient vaccination against SARS-Cov-2.

16 September 2020 in Nephrologie & Therapeutique
Verified
Journal Article
Closed access
TLThibault Letellier
Thibault Letellier
HCH. de Carvalho
H. de Carvalho
MKM. Karakachoff
M. Karakachoff
TDT. Dejoie
T. Dejoie
HCH. Caillon
H. Caillon
LFL. Figueres
L. Figueres
Introduction: L’hyponatrémie est décrite comme facteur prédictif d’une évolution péjorative dans l’infection à Sars-CoV. Quid du Sars-CoV2 ? Description: L’objectif principal était d’évaluer l’association entre une hyponatrémie (natrémie < 135 mM) à l’admission et une évolution défavorable (transfert en réanimation, ventilation mécanique et/ou décès). Méthodes: Au total, 323 patients hospitalisés entre le 1er février et le 7 mai 2020 avec un diagnostic de COVID-19 (RT-PCR SARS-CoV-2 positive sur écouvillonnage nasopharyngé ou image spécifique scanographique) ont été inclus dans notre étude monocentrique rétrospective. Les patients mineurs et 6 patients hypernatrémiques ont été exclus de l’étude. Les variables épidémiologiques, cliniques, scanographiques ont été extraites et analysés par un test de Chi2 (variables qualitatives) ou un test de Student (variables quantitatives). Une régression logistique a été réalisée avec les variables d’intérêt (p < 0,2 en analyse univariée) et en excluant les variables avec données manquantes (obésité, scanner thoracique). Résultats: Cent-un patients constituaient le groupe hyponatrémie (31 % de la cohorte), avec une proportion d’hommes significativement supérieure (p < 0,005) au groupe normonatrémie (222 patients). L’hyponatrémie était modérée dans la plupart des cas (moyenne : 132,3 mM ± 1,7 [123–134]). Douze patients avaient une natrémie inférieure à 130 mM. Le transfert en réanimation, la ventilation mécanique et le décès étaient plus fréquents dans le groupe hyponatrémie (34 versus 14 %, p < 0,001 ; 16 % versus 5 %, p < 0,01 ; 19 versus 9 %, p = 0,012, respectivement). Les patients hyponatrémiques avaient un débit d’oxygène comparable à l’admission, mais une atteinte plus étendue au scanner (35 vs 20 %, p < 0,01). En analyse multivariée incluant l’âge, le sexe, l’antécédent de diabète, la fonction rénale et le débit d’oxygène à l’admission, l’hyponatrémie était indépendamment associée à une évolution défavorable (adjusted Odds-ratio : 2,61 [1,43–4,78], p = 0,002) (Tableau 1). Conclusion: L’hyponatrémie est associée à un pronostic défavorable en cas d’infection COVID-19, et est possiblement le reflet d’une atteinte pulmonaire plus sévère.

18 October 2023 in Kidney International
Verified
Journal Article
Closed access
TLThibault Letellier
Thibault Letellier
JDJeremy Debraux
Jeremy Debraux
JGJimmy Grellier
Jimmy Grellier
RCRomain Collot
Romain Collot
GCGrégoire Couvrat-Desvergnes
Grégoire Couvrat-Desvergnes
AFAwena Le Fur
Awena Le Fur

9 February 2026 in medRxiv
Verified
Preprint
Open access
PDF file
SMS. Marchand
S. Marchand
ATA. Trochel
A. Trochel
MLM. Loirat
M. Loirat
JMJ. Mignon
J. Mignon
TLThibault Letellier
Thibault Letellier
DMDorian McILROY
Dorian McILROY
BK polyomavirus (BKPyV) is a major complication in kidney transplant recipients (KTR), for whom no specific antiviral therapy is available. Modulation of immunosuppressive therapy results in virus clearance in most KTR with BKPyV DNAemia (controllers), but a significant minority fail to clear the virus (non-controllers). Here, we adapt LIBRA-seq, which links antibody sequence data to antigen specificity, to intact viral capsids of the four BKPyV genotypes to study and compare BKPyV-specific B-cell repertoires in controllers (n=8) versus non-controllers (n=3). Sequences were obtained for 5197 BKPyV-specific antibodies, and predicted antigen specificities were validated by ELISA and neutralizing assays (n=21 antibodies). We show that cross-genotype reactivity results from the recruitment of numerous broadly cross-reactive B-cell clones with preferential binding to the infecting genotype, making up 4,3% to 44,6% of the BKPyV-specific repertoire, while true broadly neutralizing antibodies are rare. The proportions of broadly-specific and isotype switched antibodies, rates of somatic hypermutation and repertoire diversity were comparable in both patient groups, indicating that there is no identifiable deficit in the humoral response mounted by BKPyV non-controllers, and supporting the notion that humoral immunity alone is insufficient to control established BKPyV replication. This work shows that LIBRA-seq can be successfully applied to a non-enveloped virus and provides a framework for analyzing antiviral B-cell repertoires and antibody specificity in clinically relevant settings. Abstract Figure: